Entera Bio Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $436.3M
- Price
- $2.51
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.79%
- Volume
- 679.5K
About
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
Quick stats
Shares outstanding173.8M
Computed float38.0M
Float / shares21.9%
Cash runway (months)8.6
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001638097
Websitehttps://www.enterabio.com
AI Summary
AI-generated1/22
minorbullishboard change
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio appointed Laura Hamill, a former Gilead and Amgen commercial executive with over 35 years of experience, to its Board of Directors effective December 1, 2026.
Hamill most recently led Gilead's worldwide commercial operations, overseeing roughly 2,500 employees and $22 billion in annual revenue, after nearly two decades at Amgen.
The appointment adds commercial launch expertise as Entera advances its lead oral PTH(1-34) candidate EB613 toward potential commercialization in osteoporosis; she succeeds long-serving director Yonatan Malca.